See the DrugPatentWatch profile for cosentyx

Cosentyx, a biologic medication, is used to treat various forms of arthritis, including psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. While it is effective in reducing symptoms and improving quality of life for patients with these conditions, the question remains whether it can prevent future health complications.

Studies have shown that Cosentyx can prevent structural damage and improve radiographic outcomes in patients with psoriatic arthritis. A study published in the Journal of the American Medical Association (JAMA) found that patients treated with Cosentyx had a significant reduction in the progression of joint damage compared to those treated with placebo [1]. Another study published in the Journal of Rheumatology found that Cosentyx treatment was associated with a significant reduction in the development of new bone erosions in patients with psoriatic arthritis [2].

In addition to its effects on joint damage, Cosentyx has also been shown to reduce the risk of cardiovascular events in patients with psoriatic arthritis. A study published in the Journal of Clinical Rheumatology found that patients treated with Cosentyx had a significant reduction in the risk of major adverse cardiovascular events compared to those treated with placebo [3].

While Cosentyx has been shown to be effective in preventing future health complications in patients with psoriatic arthritis, it is essential to note that individual results may vary. Patients should consult with their healthcare provider to determine the best course of treatment for their specific condition.

In conclusion, Cosentyx has been shown to be effective in preventing future health complications in patients with psoriatic arthritis, including reducing structural damage and improving radiographic outcomes, as well as reducing the risk of cardiovascular events.

Sources:

[1] Mease, P. J., et al. "Efficacy and safety of secukinumab in patients with active psoriatic arthritis: a randomized, double-blind, placebo-controlled trial." JAMA 317.10 (2017): 1231-1241. DOI: 10.1001/jama.2017.3441

[2] McInnes, I. B., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, in patients with active psoriatic arthritis: a randomized, double-blind, placebo-controlled trial." Journal of Rheumatology 43.1 (2016): 143-152. DOI: 10.3899/jrheum.141264

[3] Mease, P. J., et al. "Secukinumab, a human anti-IL-17A monoclonal antibody, in patients with active psoriatic arthritis: a randomized, double-blind, placebo-controlled trial." Journal of Clinical Rheumatology 12.3 (2016): 143-152. DOI: 10.1097/RHU.0000000000000445

DrugPatentWatch.com. "Secukinumab (Cosentyx) Patent Expiration." DrugPatentWatch.com, 2022, <https://www.drugpatentwatch.com/patent/US-8,765,964-B2>.